Recent Updates
Recently added Catalysts

TV-46000

Phase 3

Schizophrenia | Small molecule | Psychiatry |Teva Pharmaceutical Industries Limited|Last Updated: Mar 10, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment880
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03893825A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaPHASE3 COMPLETED 336Apr 17, 2019Dec 2, 2021Dec 7, 202290 United States, Bulgaria +3
NCT03503318Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With SchizophreniaPHASE3 COMPLETED 544Apr 27, 2018Dec 3, 2020Mar 10, 202381 United States, Bulgaria
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Adverse Events (AEs)
Baseline up to Week 64

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Number of Participants With SAEs
Baseline up to Week 64

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. The safety analysis set included all participants who received at least 1 dose of TV46000 in TV-46000-CNS-30072 study or in TV46000-CNS-30078 study.

Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set
From randomization up to 108 weeks

Relapse was defined as 1 or more of the following items: • Clinical Global Impression-Improvement (CGI-I) of ≥5, and - an increase of any of the 4 Positive and Negative Syndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of \>4 with an absolute increase of ≥2 on specific item since randomization, or - an increase in any of the 4 individual PANSS items to a score of \>4 and an absolute increase of ≥4 on combined score of 4 items since randomization; • hospitalization due to worsening of psychotic symptoms; • Clinical Global Impression-Severity of Suicidality (CGI-SS) of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2; • violent behavior resulting in clinically significant self-injury, injury to another person, or property damage. Data is presented as distribution of relapsing participants (number of participants with impending relapse).

Secondary Endpoints
Time to Impending Relapse (Number of Participants With Impending Relapse) for Extended ITT [eITT] Analysis Set
From randomization up to 108 weeks
Proportion of Participants With Impending Relapse
Week 24
Number of Participants Who Maintain Stability at the Endpoint
At the endpoint (up to 108 weeks)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TV-46000 q1mEXPERIMENTALParticipants will receive a subcutaneous (SC) injection of TV-46000 at baseline and every 4 weeks (q4w) thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
TV-46000 q2mEXPERIMENTALParticipants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter for up to 56 weeks. The maximal dose administered to adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents is comparable to 4 mg/day.
PlaceboPLACEBO_COMPARATORParticipants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
Interventions
NameTypeDescription
TV-46000DRUGTV-46000 will be administered per dose and schedule specified in the arm description.
PlaceboDRUGPlacebo matching to TV-46000 will be administered per schedule specified in the arm description.
Unlock Study Design Details
Eligibility Criteria
Age Range13 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites90

Inclusion Criteria: Participants Rolling Over from the Pivotal Efficacy Study TV46000-CNS-30072: * The participant must have participated in the pivotal efficacy study (Study TV46000-CNS-30072) without experiencing relapse events and without important protocol deviations. * If the participant was ...

Countries:United StatesBulgariaCanadaFranceIsrael
Unlock Eligibility Criteria